Intratympanic Injections of N-acetylcysteine and Dexamethasone for Prevention of Cisplatin-induced Ototoxicity: Double Blind Randomized Clinical Trial
Phase 1
Completed
- Conditions
- hearing impairmentHearing LossIntratympanic InjectionDexamethasoneAcetylcysteine
- Registration Number
- TCTR20160314003
- Lead Sponsor
- Student Research Committee
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 114
Inclusion Criteria
first cycle of cisplatin therapy
normal tympanogram type A
normal microscopic examinations
no history of head trauma, brain tumors, severe ear infection, ear surgery, ruptured eardrums, meningoencephalitis, acoustic trauma and cranial radiation
Exclusion Criteria
Patients in the end stages of cancers or taking other ototoxic drugs
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method hearing impairment before each cycle of cisplatin therapy pure tone audiometry
- Secondary Outcome Measures
Name Time Method hearing impairment 6 months after the last cycle of cisplatin therapy pure tone audiometry